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ABSTRACT
Background and objectives: Evidence suggests that sustained virologic response to interferon 
treatment decreases incidence of hepatocellular carcinoma in patients with hepatitis C virus cir-
rhosis. This study was designed to compare the incidence of hepatocellular carcinoma among 
cirrhotic patients exposed to interferon based treatment with or without achieving a sustained vi-
rological response, in order to evaluate the role of interferon itself in the prevention hepatocellular 
carcinoma. Methods: A cohort of 85 patients with compensated hepatitis C cirrhosis was followed 
after treatment with interferon and ribavirin. Sustained virological response was defi ned as negative 
polymerase chain reaction assay 24 weeks after the end of treatment. Patients were followed every 6 
months with ultrasound and alpha-fetoprotein. Hepatocellular carcinoma was diagnosed by the fi nding 
of a focal liver lesion greater than 2 cm with arterial hypervascularization on two imaging techniques 
and/or by liver biopsy. Results: The mean follow-up time was 32.1 ± 20 months for patients who 
achieved a sustained virological response and 28.2 ± 18 months among 47 patients (55%) without 
SVR. Hepatocellular carcinoma was diagnosed in 1 (3%) vs. 8 (17%) responders and non respond-
ers respectively (p = 0.02). Conclusion: Patients with cirrhosis due to hepatitis C virus who achieved 
sustained virological response had signifi cantly lower incidence of hepatocellular carcinoma when 
compared to those without treatment response. Interferon treatment without achieving sustained 
virological response does not seem to protect against hepatocellular carcinoma.
Keywords: hepatocellular carcinoma, HCV interferon, sustained virologic response, cirrhosis.
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INTRODUCTION
Hepatitis C virus (HCV) infection is current-
ly one of the main causes of hepatocellular 
carcinoma (HCC) in Western countries.1,2 
Once HCV-related cirrhosis develops, HCC 
occurs at an annual rate of 1%-4%, al-
though studies from Japan usually report 
higher rates.3,4 In patients with HCV cir-
rhosis or bridging fibrosis, interferon (IFN) 
based therapy can achieve an overall rate of 
sustained virologic response (SVR) rang-
ing from as low as 5% to almost 50%, de-
pending on the therapeutic regimen used.5-9 
There is some evidence that IFN treatment 
can protect against the risk of HCC in HCV 
cirrhotic patients.10 This effect was reported 
in a randomized controlled trial, where 90 
patients with compensated HCV cirrhosis 
received either 6 MU of IFN-alpha three 
times a week for 24 weeks or symptomatic 
treatment. After a mean follow-up of 8.7 
years, HCC was found, respectively, in 27% 
vs. 73% of treated and non-treated indi-
viduals. Recently, several meta-analysis11-14 
have confirmed the beneficial effect of IFN 
in reducing the risk of HCC in HCV cir-
rhotic patients. However, it remains unclear 
if this protective effect is related to intrinsic 
IFN properties or if it is mainly restricted 
to patients with SVR. Therefore, the aim of 
the present study was to compare the rate 
of HCC development in a cohort of HCV 
cirrhotic patients with versus without SVR 
after IFN based treatment.
METHODS 
Study design and data collection
A cohort study was conducted at the Hos-
pital de Clínicas de Porto Alegre, Brazil, a 
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tertiary center of the Brazilian public Health System. 
Patients came to our Viral Hepatitis Outpatient Clinic 
referred from primary and secondary care centers after 
the diagnosis of chronic hepatitis C. The routine evalu-
ation of these patients includes HCV-RNA detection, 
genotyping and quantification, hematological and bio-
chemical tests, and serologic testing for hepatitis B virus 
and HIV, and an ultrasound guided percutaneous liver 
biopsy. While on interferon based treatments, patients 
were followed clinically and with biochemical and he-
matological tests every four weeks. HCV-RNA testing 
was performed before and during treatment. All patients 
were also tested at least one time six or more months 
after the end of treatment. Hepatic ultrasound scan and 
serum alpha-fetoprotein testing were performed every 
six month in cirrhotic patients. Standardized clinical 
record forms were carefully filled in at patients’ routine 
visits. Baseline and follow-up data were retrospectively 
collected from those forms.
Participants
All patients 18 years or older with histologically prov-
en HCV cirrhosis (Metavir 4 or Ishak 5-6)15 that have 
been treated with interferon-based therapies until July 
2003 were eligible to the study. Patients who complet-
ed treatment after July 2003 were not included in this 
analysis, in order to have enough follow-up time. All pa-
tients were treated with IFN alpha (either conventional 
or pegylated) plus ribavirin. Genotype 1 patients were 
treated for 48 weeks, and genotype 2 or 3 patients were 
treated for 24 weeks according to the main guidelines 
used at that time.
Patients were excluded from the study if at least one 
of the following criteria was present: co-infection with 
hepatitis B or human immunodeficiency virus; diagno-
sis of other forms of liver disease; alcohol consumption 
above 10 g/d; alpha-fetoprotein level greater than 20 ng/
mL at the baseline visit; detection of a focal liver lesion 
at baseline ultrasound scan or during the first year after 
treatment. This last criterion was adopted in order to 
prevent patients who already had HCC to be considered 
as an incident case. Patients with unstable liver disease 
were not studied, since these patients were not consid-
ered for interferon-based treatments at that time.
Variable definitions and outcomes
SVR was defined as an undetectable HCV-RNA for more 
than 24 weeks after the end of therapy. HCV-RNA was 
measured by a commercial PCR assay, with a lower limit 
of detection of 50 IU/mL.
The primary endpoint was the development of 
HCC-based on liver biopsy and/or one of the following: 
1) radiologic criteria: focal liver lesion greater than 2 cm 
detected in two imaging techniques, (computerized tomogra-
phy and magnetic resonance imaging) with hepatocellular car-
cinoma characteristics (arterial hypervascularization, wash-in 
and wash-out); 2) combined criteria: computerized tom-
ography or magnetic resonance imaging with hepato-
cellular carcinoma characteristics and alpha fetoprotein 
concentration above 400 ng/mL.16
Sample size and statistical analysis
The study was designed to have a sample size of at least 34 
patients with SVR and 34 without SVR. This 68 patients 
sample would be sufficient to detect a relative risk of 10 
with alpha of 0.05 and 80% power, given an incidence of 
outcome of 3% in non-exposed (with SVR) and 30% in 
exposed (without SVR). The sample size was increased 
to include all available patients. StatCalc, Epi-Info 3.3.2 
software, was used for sample size calculation.
Data were entered using the Epi-Info 3.3.2 software. 
The Statistical Package for the Social Sciences (SPSS 
13.0, Chicago, Il) was used for statistical analyses. Com-
parisons of means of continuous variables used t-tests 
based on linear regression models, adjusted for baseline 
measurements. P-values are based on two-sided tests 
and values < 0.05 were considered significant.
Ethical aspects
The study was conducted in accordance with the ethical 
principles of the Declaration of Helsinki, and was ap-
proved by the local Ethics Committee. All investigators 
signed a confidentiality agreement to maintain confi-
dentiality of the information obtained from the review 
of patients’ files.
RESULTS
Among the 85 HCV cirrhotic patients included in this 
study, 66% were male, and mean age was 51.9 ± 9.6 years 
(range 32-72 years). Thirty eight patients (45%) achieved 
SVR, while 47 (55%) were non-responders or relapsers. 
The mean follow-up time, measured from the last IFN 
dose up to the last recorded visit was 32.1 ± 20 months 
(range: 12-84 months) among patients with SVR and 
28.2 ± 18 months (range: 12-96 months) among patients 
without SVR. Baseline characteristics of the groups with 
and without SVR are shown in Table 1. All patients had 
at least one course of treatment with IFN (conventional 
or pegylated) plus RBV, and 17 (20%) received a second 
course of treatment.
Occurrence of HCC was observed in 1 (3%) of 38 
patients with SVR, and in 8 (17%) out of the 45 pa-
tients without SVR (OR 0.13; 95% CI 0.006-0.9, 
p = 0.02). Mean time interval between the end of therapy
and HCC diagnosis was 24 months in the patient 
with SVR, and 38.3 months in patients without SVR. 
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Figure 1 illustrates the cumulative incidence of hepato-
cellular carcinoma in patients with and without SVR.
Attributable risk (AR) may be calculated from the 
HCC risk differences between SVR and non-SVR groups, 
leading to an etiologic fraction of 14% (95% confidence 
interval: 2.5-26.3). The attributable risk in exposed indi-
viduals (%AR = [(risk in exposed – risk non-exposed)/ 
risk in exposed] x 100) is 78%.
DISCUSSION
Our data, based on a cohort of chronic hepatitis C cir-
rhotic patients previously treated with interferon and 
ribavirin, showed a significant reduction on HCC risk 
among those who achieved sustained virological response. 
The attributable risk in exposed individuals, the percent-
age of the total risk of HCC among patients without SVR 
that is attributable to not reaching SVR, shows how im-
portant SVR is in the prevention of HCC. It is correct to 
believe, based on our data, that if all patients would have 
reached SVR, 78% of the HCC in this population could 
be prevented.17
The rationale behind our study is that the risk of HCC 
in patients with chronic viral hepatitis correlates with clin-
ical and histological signs of disease severity and increased 
liver cell proliferation.18 Based on this, it has been argued 
that long-term suppression of viral replication could re-
duce hepatocyte turnover and liver cell inﬂ ammation, 
leading to a lower risk of dysplasia and cancer.14 As IFN 
alpha combines antiviral, anti-inﬂ ammatory, antifi brotic, 
and antiproliferative properties, it is conceivable that this 
agent has an intrinsic effect in primary chemoprevention 
of HCC in patients with chronic viral hepatitis or cirrhosis, 
regardless of the treatment response.
Several studies were performed to investigate the rela-
tionship between IFN-based therapy and HCC development 
in patients with HCV infection.19-32 These studies were usu-
ally based on retrospective analysis of small cohorts or small 
randomized controlled trials (RCT) and showed a marked 
degree of heterogeneity, making it diffi cult to assess the ac-
tual level of benefi t obtained by IFN treatment.
To better evaluate whether IFN reduces the incidence of 
HCC in patients with HCV cirrhosis, a previous meta-anal-
ysis13 was updated to include three randomized and 17 non-
randomized controlled trials published up to 2005, totaliz-
ing 4,659 patients.14 The results showed that IFN decreased 
HCC rate in all but one of the trials, with a signifi cant differ-
ence being observed in 13 of them. Evaluating only studies 
with consistent results, the authors found that for each 10 
patients treated with INF-based regimens, one HCC could 
be avoided (NNT = 10), including responders and non-re-
sponders. The NNT was reduced to 6 when the analysis was 
restricted to patients who had a sustained response, either 
biochemical or virological. These fi ndings are in agreement 
with our results, supporting the hypothesis that the effect 
of IFN treatment on HCC rate is more related to treatment 
response than to any direct effect of IFN on carcinogenesis. 
In the present study a NNT of 7 was found among HCV cir-
rhotic patients who achieved SVR.
Even though our study was based on a historical cohort, 
we included patients with similar baseline characteristics. 
Table 1. Demographical and clinical characteristics of patients with versus without SVR 
 SVR  Non-SVR p value
 n = 38 n = 47
Mean age, years (±SD) 51.1 ± 8.3 52.6 ± 10.5 0.5
Male gender (%) 24 (63) 32 (68) 0.4
HCV Genotype 1 (%) 5/32 (16) 16/39 (41) 0.04
Duration of infection, years (±) 22.2 ± 6.3‡ 22.5 ± 7.1§ 0.99
SVR, Sustained Virological Response; SD, Standard Deviation; HCV, Hepatitis C Virus.
Duration of infection defined as interval between exposure to risk factor (whenever identified) and treatment initiation. 
‡Data available for 24 patients; §Data available for 30 patients.
Figure 1: Cumulative incidence of hepatocellular carcinoma 
in patients with and without SVR.
Years
without RSV
with RSV
20
15
10
5
0
0 1 2 3 4 5 6 7 8
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 o
f 
H
C
C
 (
%
)
SVR, sustained virological response; HCC, hepatocellular carcinoma.
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Thus, the reduced rate of HCC occurrence observed among 
treatment responders cannot be ascribed to demographical or 
clinical differences: all patients were Child-Pugh A, without any 
past or present history of hepatic imbalance, and showed simi-
lar age and gender distribution. Nevertheless, the retrospective 
design of this study prevents unfolding the contribution of 
other existing risk factors for HCC, such as aﬂ atoxin exposure, 
occult HBV infection and/or surreptitious alcohol use.33-36
We noted a high incidence of HCC development among 
the group of patients without SVR (8 out of 45; 17%). This 
increased HCC rate could be explained in part by the fact that 
all patients were submitted to a stringent screening protocol. 
Nevertheless, this fi nding is not unusual, and is well inside the 
range found by other authors which noted HCC occurrence 
among HCV cirrhotic patients to vary from as low as 7%23 to 
as high as 38%19 during similar follow-up periods.
In the present study we detected only one case of HCC 
in the SVR group, during mean follow-up of almost three 
years. This finding, although encouraging, cannot be 
overestimated. Indeed, longer periods of follow-up will 
be required to demonstrate that SVR is truly capable of 
halting the carcinogenic process in the cirrhotic liver, in-
stead of merely delaying it. In this regard, a recent study 
from Japan37 followed 142 chronic HCV infected patients 
who achieved SVR. After a mean of approximately five 
years, de novo HCC was diagnosed in six patients (4.2%). 
This data is similar to the 3% occurrence of HCC de-
scribed in our study.
In conclusion, we found a benefi cial effect of SVR in re-
ducing HCC occurrence in a group of HCV cirrhotic pa-
tients treated with the combination of IFN plus RBV, indi-
cating that the presence of the viral agent is probably more 
important for carcinogenesis than cirrhosis itself. These 
fi ndings should encourage health care givers to strongly 
consider HCV eradication, even in the presence of cirrho-
sis, despite known diffi culties inherent to IFN-based treat-
ment in this group of patients with advanced disease. Fur-
ther studies with a prospective design, longer follow-up, and 
larger sample size are needed to establish the true role of 
HCV eradication in preventing HCC development.
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